CAJ | 학술논문

目的：探讨阿托伐他汀和辛伐他汀治疗不稳定性心绞痛(UAP)的临床疗效。方法：120例UAP患者双盲随机分为研究组和对照组各60例,在常规进行抗心绞痛用药治疗基础上,研究组加用阿托伐他汀,对照组加用辛伐他汀。观察两组血脂水平、疗效、用药期间症状发作情况、急性心脏事件和不良反应。结果：治疗后研究组患者TC、TG、LDL-C明显低于对照组,HDL-C明显高于对照组,血脂水平获得明显改善(P<0.05)；研究组患者治疗总有效率明显高于对照组(P<0.05)；研究组平均每周心绞痛发作次数和平均持续时间均明显低于对照组(P<0.05)；研究组AMI和PCI发生率均明显低于对照组(P<0.05)；心源性猝死发生率无显著差异(P>0.05)。结论：阿托伐他汀治疗UAP疗效较辛伐他汀更佳,可进一步改善患者血脂水平和心绞痛不良症状、降低急性心脏事件发生率、提高患者生活质量,同时具有较好的用药安全性。
목적：탐토아탁벌타정화신벌타정치료불은정성심교통(UAP)적림상료효。방법：120례UAP환자쌍맹수궤분위연구조화대조조각60례,재상규진행항심교통용약치료기출상,연구조가용아탁벌타정,대조조가용신벌타정。관찰량조혈지수평、료효、용약기간증상발작정황、급성심장사건화불량반응。결과：치료후연구조환자TC、TG、LDL-C명현저우대조조,HDL-C명현고우대조조,혈지수평획득명현개선(P<0.05)；연구조환자치료총유효솔명현고우대조조(P<0.05)；연구조평균매주심교통발작차수화평균지속시간균명현저우대조조(P<0.05)；연구조AMI화PCI발생솔균명현저우대조조(P<0.05)；심원성졸사발생솔무현저차이(P>0.05)。결론：아탁벌타정치료UAP료효교신벌타정경가,가진일보개선환자혈지수평화심교통불량증상、강저급성심장사건발생솔、제고환자생활질량,동시구유교호적용약안전성。
Objective:To investigate the effects of atorvastatin and simvastatin treatment of unstable angina pectoris ( UAP ) clinical curative effect. Methods:120 cases of UAP were randomly divided into study group and control group with 60 cases in each group. Study group was treated with atorvastatin and the control group was treated with simvastatin based on routine treatment antianginal medication. To observe the blood lipid levels, treatment, medication during the onset of symptoms, acute cardiac events and adverse reactions of two groups. Results:After the treatment, TC, TG, LDL-C in study group were significantly lower than those in control group, HDL-C was significantly higher than that in control group, serum lipid level was significantly improved ( P<0.05 ). The total effective rate in study group was significantly higher than control group ( P<0.05 );the average weekly anginal attack number of times and the average duration were significantly lower than those in control group ( P<0.05 ). AMI and PCI in study group were significantly lower than that in control group ( P<0.05 ). Incidence of sudden cardiac death had no significant difference between two groups ( P>0.05 ). Conclusion:Atorvastatin treatment UAP curative effect is better than simvastatin, which can further improve the level of blood lipid and angina symptoms, reduce the incidence of cardiac event, improve the quality of life of patients, and has good safety.